AllazoHealth to co-present randomized controlled, intent-to-treat study with BCBS of North Carolina at the 2017 Connected Health Conference


AllazoHealth and Blue Cross Blue Shield of North Carolina will co-present a poster at this year’s Connected Health Conference in Boston. The poster outlines a randomized controlled and intent-to-treat research study completed by AllazoHealth and BCBS North Carolina in 2016 that aimed to measure the impact of AllazoHealth-targeted interventions on medication adherence.

Working to improve the adherence rates across three medication classes for over 104,000 Medicare Advantage Part D patients, the study found that AllazoHealth-targeted interventions significantly outperformed interventions targeted through traditional methods. Results were measured by a statistical difference-in-difference comparison between the 2016 and 2015 Medicare Advantage CMS star drug category adherence rates.

Following the conference, poster abstracts will also be published online in iProceedings (

About the Connected Health Conference

The 2017 Connected Health Conference (CHC17) will convene an audience of over 2,000 healthcare providers and forward-thinking companies for three days of inspirational discussion and problem-solving. This year’s conference will include poster sessions, Innovation Challenges, and a host of speakers from a range of backgrounds and disciplines. If you’re attending CHC17, catch up with us at our poster presentation! You can find us in the exhibit hall on October 26 and 27 between10:40am and 12:40pm. Check out the full list of presentations here.

About AllazoHealth

Founded in 2011, AllazoHealth is a healthcare technology company focused on improving medication adherence through predictive analytics and artificial intelligence. Our award-winning engine helps our healthcare customers engage their patients more efficiently and effectively to achieve greater adherence uplift at a significantly lower cost.

This is accomplished through our engine’s proprietary algorithms and machine learning capabilities, which target the right adherence interventions to the right patient at exactly the right time, while simultaneously cutting-out unnecessary outreach.

Our healthcare customers, who collectively serve over 30 million patients in the U.S., include some of the largest players in the payer, pharmacy, and pharmaceutical industry.